Focused On-demand Library for Granulocyte colony-stimulating factor receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q99062

UPID:

CSF3R_HUMAN

Alternative names:

Alternative UPACC:

Q99062

Background:

The Granulocyte colony-stimulating factor receptor (G-CSFR), encoded by the gene with accession number Q99062, is pivotal in hematopoiesis. It serves as a receptor for CSF3, playing an essential role in the maturation and differentiation of cells within the neutrophil lineage. Its functions extend to promoting cell proliferation, differentiation, and survival, and it may also participate in cell surface adhesion or recognition processes.

Therapeutic significance:

G-CSFR is directly implicated in hereditary neutrophilia and severe congenital neutropenia 7, autosomal recessive, conditions marked by abnormal neutrophil counts and susceptibility to infections. Targeting G-CSFR pathways offers a promising avenue for developing treatments for these hematopoietic disorders, highlighting the receptor's therapeutic potential.